Allegro Ophthalmics
Late stage biotechnology company Allegro Ophthalmics recently announced two promotions within the company's senior management team.
Vicken Karageozian, MD, formerly Chief Technical Officer (CTO), has been named President and Chief Medical Officer. Dr. Karageozian has more than 20 years of experience in the ophthalmic pharmaceutical space and will be responsible for the development and execution of Allegro's corporate, clinical and financial strategies.
And John Park, PhD, formerly Vice President of Product Development, has been promoted to Chief Scientific Officer and Vice President of Manufacturing Development. Dr. Park has four decades of experience bringing ophthalmic drugs from concept to market, and will lead scientific discovery, preclinical development and manufacturing development to support Allegro's drug platform, including that of Luminate.
Click here to read the full press release.